+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a new multivalent pneumococcal conjugate vaccine called PG4 in adults aged 18 to 49 years. The study compares three different production lots of the PG4 vaccine to each other and to an existing 20-valent pneumococcal conjugate vaccine 20vPnC to confirm consistent vaccine performance and safety. Participants are randomly assigned to one of four groups three groups receive one of the three different lots of the PG4 vaccine, and the fourth group receives the 20vPnC vaccine. Each participant receives a single injection of their assigned vaccine in the arm. The study uses a randomized, double-blind design with groups allocated in a 2221 ratio to ensure balanced comparison. During the approximately six-month study participation, blood samples are collected to measure immune responses and monitor safety. Researchers assess local and systemic reactions within one week after vaccination, adverse events up to one month, and serious adverse events up to six months. They also analyze specific antibody levels and immune activity to evaluate how the vaccines stimulate the bodys defenses against pneumococcal disease.

Age: 18Years - 49YearsAll GendersPhase 3
37 locations
A

Actively Recruiting

Researchers are studying VX-993 to evaluate its effectiveness, safety, and tolerability in adults with pain caused by Diabetic Peripheral Neuropathy DPN, a condition linked to diabetes that affects nerve function in the lower limbs. This Phase 2 trial compares VX-993 with Pregabalin, an existing medication used to manage this type of pain, to better understand how these treatments work for participants with DPN. Participants are randomly assigned to receive either varying doses of oral VX-993 tablets or Pregabalin capsules. The study is double-blind and includes matched placebos for both treatments to maintain unbiased results. The trial lasts up to 16 weeks, with primary evaluations focused at 12 weeks to measure changes in pain intensity using a numeric scale. During the trial, participants will undergo regular assessments of their daily pain levels and monitoring for any adverse effects. Researchers will track the percentage of pain reduction and evaluate safety through reports of side effects. The study spans from initial screening through treatment and follow-up, with ongoing safety assessments to support participant well-being throughout the process.

Age: 18Years - 80YearsAll GendersPhase 2
47 locations